drugset / Trial / NCT03254784

A Study to Evaluate BMS-986165 Tablet Formulation Relative to BMS-986165 Capsule Formulation and the Effect of a High-Fat/ High-Calorie Meal and Increased Gastric pH on the BMS-986165 Tablet Formulation

NCT03254784

Phase 1 Completed 49 enrolled Bristol-Myers Squibb
RandomizedCrossoverOpen-labelTreatment

Summary

The purpose of this study is to evaluate BMS-986165 tablet formulation versus BMS-986165 capsule formulation. This study will also evaluate the effect of a high-fat/ high-calorie meal and increased gastric pH on the BMS-986165 tablet formulation.

Timeline

Start
2017-09-13
Primary completion
2017-11-04
Completion
2017-11-15

Drugs

EvaluationDrugModalityDoseRoute
Subject CRAVACITINIB Small molecule Oral